Asia-Pacific

The next round of uncertainty – ‘a headwind and a tailwind’

As the secondaries market braces itself for the next round of macroeconomic uncertainty, there is a playbook based on previous choppy markets.

Are GP-led secondaries deals and evergreen funds a good match?

With evergreen fund investment in GP-led deals on the rise, how compatible are these transactions with vehicles that offer investors a degree of periodic liquidity and, in most cases, diversified exposures?

Secondaries Awards 2025: Asia-Pacific winners

The top secondaries deals, firms, law firms and advisers of the year from the APAC region.

GP-leds boost exits for Azalea’s offerings

Temasek’s Azalea Investment Management expects more GPs to use the technology to crystallise liquidity for LPs, according to managing director Justin Keh.

GIC emerges as lead buyer on Meridiam’s €2bn+ CV

The structure will consist of a portfolio of 22 infrastructure assets that are held by the firm’s legacy funds.

Secondaries Investor full-year 2025 CV Deal Log

Last year saw 85 continuation vehicles close, with 40 more launching or being mulled, according to data gathered by Secondaries Investor.

Evercore taps Adams Street Partners for new APAC secondaries head

The appointment follows the departure of former managing director and head of Evercore’s Asia-Pacific private capital advisory team Shane Gong, who left in January 2025.

Japanese VCs face DPI hurdles under new listing rules

The Tokyo Stock Exchange is increasing minimum market capitalisation for companies listed in its Growth Market section to ¥10bn by 2030, which could have knock-on implications for secondaries activity.

VCs mull the relative attractions of IPOs and secondaries

Will we finally see a wave of IPOs this year, or will VC GPs have to turn to the secondaries market to deliver liquidity to their investors?

More than a quarter of single-family offices plan to increase secondaries exposure – JPMorgan

Around two-thirds of the over 300 family offices surveyed by JPMorgan have no exposure to secondaries.